Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer

DOI: 10.1038/s41416-018-0147-1
British Journal of Cancer, 2018, 119, 266-273.

#	Paper	IF	Citations
41	EMERGING BIOSIMILARS IN ONCOLOGY: A REVIEW. *Asian Journal of Pharmaceutical and Clinical Research*, **2018**, 11,	0.4	
40	PF-05280014: A Trastuzumab Biosimilar. *BioDrugs*, **2018**, 32, 515-518	7.9	2
39	Can we establish a hierarchy among trastuzumab biosimilar candidates?. *British Journal of Cancer*, **2018**, 119, 263-265	8.7	4
38	The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. *British Journal of Cancer*, **2019**, 121, 199-210	8.7	31
37	Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. *Targeted Oncology*, **2019**, 14, 647-656	5	6
36	Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *BioDrugs*, **2019**, 33, 357-371	7.9	6
35	Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin) in patients with HER2-positive metastatic breast cancer. *Cancer Chemotherapy and Pharmacology*, **2019**, 84, 83-92	3.5	3
34	Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review. *Breast Cancer Research and Treatment*, **2019**, 176, 17-25	4.4	2
33	Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer. *Future Oncology*, **2019**, 15, 1353-1361	3.6	6
32	What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?. *Breast Care*, **2019**, 14, 10-16	2.4	9
31	Biosimilar Trastuzumab in Clinical Trials: Differences or Not?. *Breast Care*, **2019**, 14, 17-22	2.4	5
30	Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States. *Therapeutic Advances in Medical Oncology*, **2019**, 11, 1758835919887044	5.4	13
29	[Biosimilars antibodies: positioning compared to originators - the experience in rheumatology and the biosimilars of trastuzumab in oncology]. *Medecine/Sciences*, **2019**, 35, 1137-1145		
28	PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. *British Journal of Cancer*, **2019**, 120, 172-182	8.7	26
27	Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. *Journal of Cellular Physiology*, **2020**, 235, 3142-3156	7	25
26	Towards personalized treatment for early stage HER2-positive breast cancer. *Nature Reviews Clinical Oncology*, **2020**, 17, 233-250	19.4	71
25	Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials. *Cancer Chemotherapy and Pharmacology*, **2020**, 86, 577-588	3.5	0

24	Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars. *Drugs*, **2020**, 80, 1811-1830	12.1	8
23	Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. *Journal of Clinical Oncology*, **2020**, 38, 1070-1080	2.2	9
22	How can biosimilars change the trajectory of breast cancer therapy?. *Expert Review of Anticancer Therapy*, **2020**, 20, 325-328	3.5	6
21	A Clinical Review of Biosimilars Approved in Oncology. *Annals of Pharmacotherapy*, **2021**, 55, 362-377	2.9	1
20	Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis. *Therapeutic Advances in Medical Oncology*, **2021**, 13, 17588359211006948	5.4	1
19	Trastuzumab immunogenicity development in patientsSsera and in laboratory animals. *BMC Immunology*, **2021**, 22, 15	3.7	3
18	Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial. *BioDrugs*, **2021**, 35, 337-350	7.9	3
17	Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies. *Journal of Oncology Pharmacy Practice*, **2021**, 27, 1195-1204	1.7	1
16	TROIKA-1: A double-blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU-Herceptin and US-Herceptin in healthy male subjects. *Pharmacology Research and Perspectives*, **2021**, 9, e00839	3.1	0
15	Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars. *Future Oncology*, **2021**, 17, 2529-2544	3.6	3
14	Physicochemical stability of PF-05280014 (trastuzumab-qyyp; Trazimera), a trastuzumab biosimilar, under extended in-use conditions.. *Journal of Oncology Pharmacy Practice*, **2022**, 10781552221074649	1.7	
13	Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis.. *JAMA Oncology*, **2022**,	13.4	0
12	Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.. *BioDrugs*, **2022**, 36, 55-69	7.9	0
11	Trastuzumab in breast cancer treatment: the Era of biosimilars.. *Anti-Cancer Agents in Medicinal Chemistry*, **2022**,	2.2	
10	Biosimilar Monoclonal Antibodies in Latin America.		
9	A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab. *Current Oncology*, **2022**, 29, 4224-4234	2.8	
8	Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis. *Immunopharmacology and Immunotoxicology*, 1-7	3.2	0
7	A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients. **2022**, 23,		0

6	Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer. **2022**, 10, 2045	0
5	Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China. 1-10	
4	Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial. **2022**, 22,	0
3	Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer an Analysis of a Large University Breast Cancer Centre.	0
2	Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis. **2023**, 37, 205-218	0
1	Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis. **2023**,	0